Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease

European Journal of Pharmacology

Volumn 659, Issue 2-3, 2011, Pages 289-295

  Ibrahim, Mohamed ^a   Farghaly, Entesar ^a   Gomaa, Wafaey ^a   Kelleni, Mina ^a   Abdelrahman, Aly Mohamed ^a  

^a Minia University   (Egypt)

Author keywords

Aspirin; NAFLD; NO aspirin

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; CYCLOOXYGENASE 2; MALONALDEHYDE; NITRIC OXIDE; NITRIC OXIDE ACETYLSALICYLIC ACID; NITRIC OXIDE SYNTHASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE LEVEL; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANIMALS; ASPIRIN; CYCLOOXYGENASE 2; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIVER; MALE; MALONDIALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 79955940888     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.016     Document Type: Article

References (45)

1. Anstee, Q.M., Goldin, R.D., 2006. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1-16.
2. Bellentani, S., Marino, M., 2009. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 8, S4-S8.
3. Chen, T., Zamora, R., Zuckerbraun, B., Billiar, T., 2003. Role of nitric oxide in liver injury. Curr. Mol. Med. 3, 519-526.
4. Chikako, N., Zhang, S., Vyselaar, J.R., Nozaki, Y., Nemoto, Y., Ono, M., Akisawa, N., Saibara, T., Hiroi, M., Enzan, H., Onishi, S., 2004. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 40, 781-786. (Pubitemid 38507358)
5. Chitturi, S., Abeygunasekera, S., Farrell, G.C., Holmes-Walker, J., Hui, J.M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J., 2002. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35, 373-379. (Pubitemid 34106377)
6. Cirino, G., Wheeler-Jones, C.P., Wallace, J.L., Del Soldato, P., Baydoun, A.R., 1996. Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal antiinflammatory derivatives with gastrointestinal-sparing properties. Br. J. Pharmacol. 117, 1421-1426.
7. Claudio, N., Ackah, E., Nigris, F., Del Soldato, P., D'Armiento, F., Crimi, E., Condorelli, M., Sessa, W., 2002. Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proc. Natl. Acad. Sci. 99, 12467-12470.
8. De Oliveira, C., Simplicio, F., de Lima, V., Yuahasi, K., Lopasso, F., Alves, V., Abdalla, D., Carrilho, F., Laurindo, F., de Oliveira, M., 2006. Oral administration of S-nitroso-N-acetylcysteine prevents the onset of non alcoholic fatty liver disease in rats. World J. Gastroenterol. 12, 1905-1911.
9. Esposito, E., Lacono, A., Bianco, G., Autore, G., Cuzzocera, S., Vajro, P., 2009. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J. Nutr. 139, 905-911.
10. Fan, J.G., Qiao, L., 2009. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat. Dis. Int. 8, 233-240.
11. Farrell, G.C., Larter, C.Z., 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112.
12. Fiorucci, S., Santucci, L., Antonelli, E., Distrutti, E., Del Sero, G., Morelli, O., Romani, L., Federici, B., Del Soldato, P., Morelli, A., 2000. NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology 118, 404-421. (Pubitemid 30067514)
13. Fiorucci, S., Mencarelli, A., Meneguzzi, A., Lechi, A., Morelli, A., Del Soldato, P., Minuz, P., 2002. NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation 106, 3120-3125. (Pubitemid 35440298)
14. Folch, J., Lees, M., Soloanae-Stanley, G.H., 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biochem. 226, 497-501.
15. Forstermann, U., Closs, E.I., Pollock, J.S., Nakane, M., Schwarz, P., Gath, I., Kleinert, H., 1994. Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension 23, 1121-1131. (Pubitemid 24180877)
16. George, J., Pera, N., Phung, N., Leclercq, I., Hou, Y.J., Farrell, G., 2003. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 39, 756-764. (Pubitemid 37372185)
17. Green, L.C., Wagner, D.A., Glagowski, J., Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R., 1982. Analysis of nitrate, nitrite and N nitrate in biological fluids. Anal. Biochem. 126, 131-138.
18. Grilli, M., Chiu, J., Lenardo, M.J., 1993. NF-kappaB and Rel: participants in a multiform transcriptional regulatory system. Int. Rev. Cytol. 143, 1-62.
19. Hawkey, C.J., Jones, J.I., Atherton, C.T., Skelly, M.M., Bebb, J.R., Fagerholm, U., Jonzon, B., Karlsson, P., Bjarnason, I.T., 2003. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibitor nitric oxide donator: proof of concept study in humans. Gut 52, 1537-1542. (Pubitemid 37363434)
20. Hennes, H., Smith, D.S., Schneider, K., Hegenbarth, M.A., Duma, M.A., Juda, Z., Jona, J.Z., 1990. Elevated liver transaminase levels in children with blunt abdominal trauma: a predictor of liver injury. Pediatrics 86, 87-90. (Pubitemid 20198463)
21. Ibrahim, M.A., Ashour, O.M., Ibrahim, Y.F., El-Bitar, H.I., Gomaa, W., Abdel-Rahim, S.R., 2009. Angiotensin-converting enzyme inhibition and angiotensin AT-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol. Res. 60, 373-381.
22. Son, I.S., Kim, J.H., Sohn, H.Y., Kim, J.S., Kwon, C.S., 2007. Antioxidative and hypolipedimic effects of Diosgenin, a steroidal sapon of Yam (Dioscorea spp.), on high-cholesterol fed rats. Biosci. Biotechnol. Biochem. 71, 3063-3071.
23. Jobgen, W.S., Fried, S.K., Fu, W.J., Cynthia, M.J., Wu, G., 2006. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J. Nutr. Biochem. 17, 571-588.
24. Knight, S., Johns, E.J., 2005. Effect of COX inhibitors and NO on renal hemodynamics following ischemia-reperfusion injury in normotensive and hypertensive rats. Am. J. Physiol. 58, 1072-1077.
25. Koeppel, T.A., Mihaljevic, N., Kraenzlin, B., Loehr, M., Jesenofsky, R., Post, S., Palma, P., 2007. Enhanced iNOS gene expression in the steatotic rat liver after normothermic ischemia. Eur. Surg. Res. 39, 303-311.
26. Kwiecien, S.S., Pawlik, M.W., Brzozowski, T., Konturek, P.C., Sliwowski, Z., Pawlik, W.W., Konturek, S.J., 2008. Nitric oxide (NO)-releasing aspirin and (NO) donors in protection of gastric mucosa against stress. J. Physiol. Pharmacol. 59, 103-115.
27. Mariotto, S., Cuzzolin, L., Adami, A., Del Soldato, P., Suzuki, H., Benoni, G., 1995. Inhibition by sodium nitroprusside of the expression of inducible nitric oxide synthase in rat neutrophils. Br. J. Pharmacol. 114, 1105-1106.
28. Mark, N., Paul, C., 2008. Non alcoholic fatty liver disease. The mist gradually clears. J. Hepatol. 48, 104-112.
29. McAvoy, N.C., Ferguson, J.W., Campbell, I.W., Hayes, P.C., 2006. Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. Br. J.DiabetesVasc.Dis. 6, 251-260.
30. McCullough, A.J., 2006. Pathophysiology of nonalcoholic steatohepatitis. Clin. Gastroenterol. 40, S17-29.
31. McKim, S.E., Gäbele, E., Isayama, F., Lambert, J.C., Tucker, L.M., Wheeler, M.D., Connor, H.D., Mason, R.P., Doll, M.A., Hein, D.W., Arteel, G.E., 2003. Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology 125, 1834-1844. (Pubitemid 37500447)
32. McLoughlin, C.M., Keeble, J., Moore, P.K., 1999. Effect of nitroflurbiprofen on lipopolysaccharide induced sepsis. Mediators of Inflammation 8, 146-152.
33. Nanji, A.A., Jokelainen, K., Tipoe, G.L., Rahemtulla, A., Dannenberg, A.J., 2001. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J. Pharmacol. Exp. Ther. 299, 638-644.
34. Park, S.K., Lin, H.L., Murrhy, S., 1994. Nitric oxide limits transcriptional induction of nitric oxide synthase in CNS glial cells. Biochem. Biophys. Res. Commun. 201, 762-767.
35. kBα by nitric oxide mediates inhibition of NF-kB. J. Biol. Chem. 270, 14214-14219.
36. Perez-Sala, D., Lamas, S., 2001. Regulation of cyclooxygenase-2 expression by nitric oxide in cells. Antioxid. Redox Signal. 3, 231-248.
37. Ricardo, C., Guillén, N., Arbonés-Mainar, J.M., Navarro, M.A., Guzmán, M.A., Barranquero, C., Arnal, C., Gascón, S., Acín, S., Mourelle, M., Osada, J., 2009. Nitric oxide-releasing agent, LA419, reduces atherogenesis in apolipoprotein E-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 379, 489-500.
38. Roeschlau, P., Bernt, E., Gruber, W., 1974. Enzymatic determination of total cholesterol in serum. Z. Klin. Chem. Klin. Biochem. 12, 226.
39. Sherman, M.P., Aeberhard, E.E., Wong, V.Z., Griscavage, J.M., Ignarro, L.J., 1993. Pyrrolidine dithiocarbamate inhibits induction of nitric oxide synthase activity in rat alveolar macrophages. Biochem. Biophys. Res. Commun. 191, 1301-1308.
40. Thong-Ngam, D., Samuhasaneeto, S., Kulaputana, O., Klaikeaw, N., 2007. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. World J. Gastroenterol. 13, 5127-5132.
41. Tipoe, G.L., HO, C.T., Liong, E.C., Leung, T.M., Lau, T.H., Fung, M.L., Nanji, A., 2009. Voluntary oral feedingof ratsnot requiring a very highfatdiet is a clinically relevantanimalmodel of non-alcoholic fatty liver disease (NAFLD). Histol. Histopathol. 24, 1161-1169.
42. Uchiyama, M., Mihara, M., 1979. Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 86, 271-278.
43. Xie, Q.-W., Whisnant, R., Nathan, C., 1993. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and lipopolysaccharide. J. Exp. Med. 177, 1779-1784.
44. Xu, P., Xing-guo, Z., You-ming, L., Chao-hui, Y., Xu, L., Xu, G., 2006. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J. Zhejiang Univ. Sci. 7, 627-633.
45. Yuan, G.J., Zhou, X.R., Gong, Z.J., Zhang, P., Sun, X.M., Zheng, S.H., 2006. Expression and activity of inducible nitric oxide synthase and endothelial nitric oxide synthase correlate with ethanol-induced liver injury. World J. Gastroenterol. 12, 2375-2381.